Sillecton launches first site for SIL204 Phase 2/3 in pancreatic cancer
SLXN Silexion Therapeutics Corp
$1.84 +15.00%
차트·분석 보기 → - 1Sillecton Therapeutics (SLXN) has launched a Phase 2/3 trial of SIL204 at Tel Aviv's Sourasky Medical Center.
- 2The study targets locally advanced pancreatic cancer in combination with standard chemotherapy, enrolling an initial safety run-in of about 18 patients before expanding to a randomized cohort of roughly 166.
- 3With the first site now active, patient screening can begin within weeks, and the company said it has shifted from regulatory preparation to clinical execution.
This 3-line summary is compiled from the report below.
FinanceWire +1 View original ↗🎯 오늘의 AI 픽 5종목, 무료로 전부 공개합니다
숨기는 것 없이 — 지난 픽의 성적표(S&P500 대비)까지 그대로 보여드립니다